Obesity-Drug Price War Rattles Healthcare Sector as Rivals Clash

The market volatility centered on Novo Nordisk, which saw its shares continue a downward slide after the Danish pharmaceutical giant accused Hims & Hers of "illegal mass compounding." The legal friction intensified after the telehealth platform announced it would sell compounded versions of Wegovy for an introductory price of $49 for the first month. Despite the aggressive pricing strategy aimed at capturing market share, Hims & Hers stock also fell alongside the broader sector.

Market Reaction and Sector Performance

The ripple effects hit Eli Lilly, whose shares fell sharply, reversing major gains previously fueled by strong quarterly earnings for its blockbuster drug Zepbound. Investors remain wary that the entry of cheaper, compounded alternatives could erode the premium margins of pharmaceutical giants that currently dominate the obesity treatment landscape. This sentiment weighed heavily on the industry, with UnitedHealth Group leading a broader retreat among health insurers.

Performance across the sector remained mixed as specific corporate results provided some insulation. Cigna shares rose after the company reported that growth in its Evernorth pharmacy-benefit unit effectively neutralized weaknesses in other divisions. Meanwhile, drug wholesaler Cardinal Health saw its shares surge after raising its annual profit forecast, citing robust demand for its services.